These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 3109066

  • 21. DDAVP, cryoprecipitate, and highly 'purified' factor VIII concentrate in uremia.
    Juhl A.
    Nephron; 1986; 43(4):305-6. PubMed ID: 3090461
    [No Abstract] [Full Text] [Related]

  • 22. DDAVP-induced increases in coagulation factor VIII and von Willebrand factor in the plasma of conscious dogs.
    Johnson GS, Kraus KH, Turrentine MA, Dean PW.
    J Vet Pharmacol Ther; 1986 Dec; 9(4):370-5. PubMed ID: 3100823
    [Abstract] [Full Text] [Related]

  • 23. Endothelial stimulation by DDAVP in von Willebrand's disease and haemophilia.
    Greer IA, McLaren M, Belch JJ, Lowe GD, Forbes CD.
    Haemostasis; 1986 Dec; 16(1):15-9. PubMed ID: 3084364
    [Abstract] [Full Text] [Related]

  • 24. Effect of exercise, DDAVP, and epinephrine on the factor VIII:C/von Willebrand factor complex in normal dogs and von Willebrand factor deficient Doberman pinscher dogs.
    Meyers KM, Wardrop KJ, Dodds WJ, Brassard J.
    Thromb Res; 1990 Jan 01; 57(1):97-108. PubMed ID: 2105540
    [Abstract] [Full Text] [Related]

  • 25. Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects.
    Takahashi H, Itoh M, Kobayashi I, Sakuragawa N, Shibata A.
    Tohoku J Exp Med; 1980 Oct 01; 132(2):133-40. PubMed ID: 6777902
    [Abstract] [Full Text] [Related]

  • 26. [Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis].
    Köhler M, Kotitschke R, Braun B, Hellstern P, Mörsdorf S, Pindur G, Heiden M, Wenzel E.
    Beitr Infusionsther; 1990 Oct 01; 26():136-41. PubMed ID: 1703813
    [Abstract] [Full Text] [Related]

  • 27. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ, van de Velde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z.
    Semin Thromb Hemost; 2002 Apr 01; 28(2):111-32. PubMed ID: 11992235
    [Abstract] [Full Text] [Related]

  • 28. The use of desmopressin (DDAVP) in the preparation of improved factor VIII concentrate.
    Mikaelsson M, Nilsson IM, Cedergren B, Jonsson S, Rydberg L, Wiechel B.
    Scand J Haematol Suppl; 1984 Apr 01; 40():93-101. PubMed ID: 6433478
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The release of factor VIII and tissue plasminogen activator can not be blocked by specific antagonists to vasopressin.
    Vilhardt H, Barth T.
    J Recept Res; 1991 Apr 01; 11(1-4):239-45. PubMed ID: 1909360
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Fibrinolytic responses to 1-desamino-8-D-arginine-vasopressin in patients with congenital nephrogenic diabetes insipidus.
    Knoers N, Brommer EJ, Willems H, van Oost BA, Monnens LA.
    Nephron; 1990 Apr 01; 54(4):322-6. PubMed ID: 2109264
    [Abstract] [Full Text] [Related]

  • 33. Vasopressin antagonist inhibition of clotting factor release in the rhesus monkey (Macaca mulatta).
    Kinter LB, McConnell I, Goodwin BT, Campbell S, Huffman WF, Arthus MF, Lonergan M, Bichet DG.
    J Pharmacol Exp Ther; 1992 May 01; 261(2):462-9. PubMed ID: 1578361
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion.
    Casonato A, Pontara E, Boscaro M, Dannhauser D, Sartori MT, Girolami A.
    Haematologia (Budap); 1993 May 01; 25(1):57-67. PubMed ID: 8339998
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Two distinct pathophysiological mechanisms in congenital nephrogenic diabetes insipidus.
    Moses AM, Miller JL, Levine MA.
    J Clin Endocrinol Metab; 1988 Jun 01; 66(6):1259-64. PubMed ID: 3131381
    [Abstract] [Full Text] [Related]

  • 38. Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis.
    Arshad F, Stoof SC, Leebeek FW, Ruitenbeek K, Adelmeijer J, Blokzijl H, van den Berg AP, Porte RJ, Kruip MJ, Lisman T.
    Liver Int; 2015 Jul 01; 35(7):1809-15. PubMed ID: 25522671
    [Abstract] [Full Text] [Related]

  • 39. A pilot study; desmopressin (DDAVP) in the treatment of deep venous thrombosis.
    Törnebohm E, Bratt G, Granqvist S, Lockner D, Egberg N.
    Thromb Res; 1987 Mar 01; 45(5):635-43. PubMed ID: 3109064
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.